share_log

Ocugen | 8-K: Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen | 8-K: Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen | 8-K：Ocugen提供2024年第三季度财务业绩的最新业务情况
美股SEC公告 ·  2024/11/08 13:45

Moomoo AI 已提取核心信息

Ocugen announced Q3 2024 financial results and secured $30 million in debt financing, extending its cash runway into Q1 2026. The company reported operating expenses of $14.4 million, including $8.1 million in R&D and $6.3 million in G&A expenses. Cash and restricted cash totaled $39.0 million as of September 30, 2024.The company's gene therapy programs showed significant progress, with OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa on track to complete enrollment in 1H2025. OCU410 has advanced to Phase 2 of the Phase 1/2 ArMaDa trial for geographic atrophy, while the DSMB approved enrollment for the second phase of OCU410ST's GARDian trial. The FDA also cleared the IND application for OCU200's Phase 1 trial.Health Canada approved OCU400 trial expansion to Canadian sites, potentially broadening commercialization opportunities. The FDA approved an Expanded Access Program for adult RP patients, targeting a combined market of 300,000 patients across the U.S., Canada, and Europe. New data from ongoing trials will be presented at an upcoming Clinical Showcase on November 12, 2024.
Ocugen announced Q3 2024 financial results and secured $30 million in debt financing, extending its cash runway into Q1 2026. The company reported operating expenses of $14.4 million, including $8.1 million in R&D and $6.3 million in G&A expenses. Cash and restricted cash totaled $39.0 million as of September 30, 2024.The company's gene therapy programs showed significant progress, with OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa on track to complete enrollment in 1H2025. OCU410 has advanced to Phase 2 of the Phase 1/2 ArMaDa trial for geographic atrophy, while the DSMB approved enrollment for the second phase of OCU410ST's GARDian trial. The FDA also cleared the IND application for OCU200's Phase 1 trial.Health Canada approved OCU400 trial expansion to Canadian sites, potentially broadening commercialization opportunities. The FDA approved an Expanded Access Program for adult RP patients, targeting a combined market of 300,000 patients across the U.S., Canada, and Europe. New data from ongoing trials will be presented at an upcoming Clinical Showcase on November 12, 2024.
Ocugen宣布其2024年第三季度财务结果，并获得3000万美元的债务融资，将其现金流延长至2026年第一季度。该公司报告的营业费用为1440万美元，其中包括810万美元的研发费用和630万美元的销售及行政费用。截至2024年9月30日，现金及限制性现金总额为3900万美元。该公司的基因治疗项目取得显著进展，OCU400针对视网膜色素变性（retinitis pigmentosa）的III期liMeliGht试验预计将在2025年上半年完成入组。OCU410已进入地理性萎缩的I/II期ArMaDa试验的II期，而DSMB批准了OCU410ST的GARDian试验的第二阶段入组。FDA还批准了...展开全部
Ocugen宣布其2024年第三季度财务结果，并获得3000万美元的债务融资，将其现金流延长至2026年第一季度。该公司报告的营业费用为1440万美元，其中包括810万美元的研发费用和630万美元的销售及行政费用。截至2024年9月30日，现金及限制性现金总额为3900万美元。该公司的基因治疗项目取得显著进展，OCU400针对视网膜色素变性（retinitis pigmentosa）的III期liMeliGht试验预计将在2025年上半年完成入组。OCU410已进入地理性萎缩的I/II期ArMaDa试验的II期，而DSMB批准了OCU410ST的GARDian试验的第二阶段入组。FDA还批准了OCU200的I期试验的IND申请。加拿大卫生部批准OCU400试验扩展到加拿大场所，可能拓宽商业化机会。FDA批准了一项针对成人RP患者的扩展获取计划，目标是在美国、加拿大和欧洲的患者总市场达到30万名。最新的正在进行的试验数据将于2024年11月12日在即将举行的临床展示会上公布。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 114.220
    ABVC BioPharma
    ABVC
    -- 1.0600
    bluebird bio
    BLUE
    -- 4.880
    NLS Pharmaceutics
    NLSP
    -- 1.5400
    DBV Technologies
    DBVT
    -- 6.820
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日